Lomotil Dosing and Safety Considerations

Introduction to Lomotil

• The American Gastroenterological Association recommends loperamide as the first-line treatment for diarrhea management because it is more effective with fewer central nervous system effects than Lomotil 1, 2

Critical Safety Considerations

• Lomotil is not the preferred first-line agent for diarrhea management due to its lower efficacy and higher risk of central and peripheral side effects compared to loperamide 2
• Lomotil should never be used in severe dysentery with high fever or bloody stools 1
• Lomotil should be avoided in suspected infectious diarrhea caused by invasive organisms like Shigella, Salmonella, or STEC 1

Clinical Context for Use

• The American Gastroenterological Association lists Lomotil as an alternative option for loperamide-refractory therapy-associated diarrhea in cancer patients, but only after exclusion of infectious causes and with careful risk-benefit assessment in neutropenic patients 3, 4
• In cancer patients, Lomotil is considered a third-line option after loperamide and octreotide have been tried 3, 4